title: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
abstract: Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Ross L
authors.initials: RL
authors.lastname: Levine
authors.forename: Marc
authors.initials: M
authors.lastname: Loriaux
authors.forename: Brian J P
authors.initials: BJ
authors.lastname: Huntly
authors.forename: Mignon L
authors.initials: ML
authors.lastname: Loh
authors.forename: Miroslav
authors.initials: M
authors.lastname: Beran
authors.forename: Eric
authors.initials: E
authors.lastname: Stoffregen
authors.forename: Roland
authors.initials: R
authors.lastname: Berger
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Clark
authors.forename: Stephanie G
authors.initials: SG
authors.lastname: Willis
authors.forename: Kim T
authors.initials: KT
authors.lastname: Nguyen
authors.forename: Nikki J
authors.initials: NJ
authors.lastname: Flores
authors.forename: Elihu
authors.initials: E
authors.lastname: Estey
authors.forename: Norbert
authors.initials: N
authors.lastname: Gattermann
authors.forename: Scott
authors.initials: S
authors.lastname: Armstrong
authors.forename: A Thomas
authors.initials: AT
authors.lastname: Look
authors.forename: James D
authors.initials: JD
authors.lastname: Griffin
authors.forename: Olivier A
authors.initials: OA
authors.lastname: Bernard
authors.forename: Michael C
authors.initials: MC
authors.lastname: Heinrich
authors.forename: D Gary
authors.initials: DG
authors.lastname: Gilliland
authors.forename: Brian
authors.initials: B
authors.lastname: Druker
authors.forename: Michael W N
authors.initials: MW
authors.lastname: Deininger
mesh_terms: D000368:Aged; D000483:Alleles; D019943:Amino Acid Substitution; D016022:Case-Control Studies; D004789:Enzyme Activation / Q000235:genetics; D005260:Female; D006801:Humans; D053614:Janus Kinase 2; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000201:enzymology / Q000235:genetics; D007945:Leukemia, Lymphoid / Q000201:enzymology / Q000235:genetics*; D007951:Leukemia, Myeloid / Q000201:enzymology / Q000235:genetics*; D015477:Leukemia, Myelomonocytic, Chronic / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2